Warfarin Sodium
Brand names: Warfarin Sodium, Jantoven
Part of: Blood thinners
At a glance
- Medicare prescriptions, 2024
- 4,233,205
- Medicare drug cost
- $39.3M
- Average cost per prescription
- $9.28
- Clinicians who prescribed it
- 97,286
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Warfarin sodium tablets are indicated for: Prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism (PE). Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation (AF) and/or cardiac valve replacement. Reduction in the risk of death, recurrent myocardial infarction (MI), and thromboembolic events such as stroke or systemic embolization after myocardial infarction. Limitations of Use Warfarin sodium tablets have no direct effect on an established thrombus, nor does it reverse ischemic tissue damage. Once a thrombus has occurred, however, the goals of anticoagulant treatment are to prevent further extension of the formed clot and to prevent secondary thromboembolic complications that may result in serious and possibly fatal sequelae.
From the FDA-approved prescribing information (label dated June 2025). Full labels on DailyMed (opens in a new tab)
Boxed warning
WARNING: BLEEDING RISK Warfarin sodium can cause major or fatal bleeding. Perform regular monitoring of INR in all treated patients. Drugs, dietary changes, and other factors affect INR levels achieved with warfarin sodium therapy. Instruct patients about prevention measures to minimize risk of bleeding and to report signs and symptoms of bleeding. WARNING: BLEEDING RISK See full prescribing information for complete boxed warning. Warfarin sodium can cause major or fatal bleeding. Perform regular monitoring of INR in all treated patients. Drugs, dietary changes, and other factors affect INR levels achieved with warfarin sodium therapy. Instruct patients about prevention measures to minimize risk of bleeding and to report signs and symptoms of bleeding.
The FDA’s strongest warning on a label. It doesn’t mean the drug is unsafe for most people; talk to your doctor or pharmacist before stopping or changing any medicine.
Who prescribes it
- Family Medicine 27.5%
- Internal Medicine 21.8%
- Nurse Practitioners 17.0%
- Cardiology 12.9%
- Physician Assistants 4.7%
- Interventional Cardiology 4.2%
- Pharmacists 2.9%
- Geriatric Medicine 1.7%
- Hematology & Oncology 1.6%
- Cardiac Electrophysiology 1.5%
- General Practice 0.8%
- Heart Failure & Transplant Cardiology 0.6%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions fell 52% from 2019 to 2024.
Biggest change by state since 2019
- South Dakota −37%
- Wyoming −38%
- North Dakota −39%
- Minnesota −39%
- Utah −40%
- Rhode Island (smallest change) −63%
- Connecticut (smallest change) −62%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 5 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Aphena Pharma Solutions - Tennessee, LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 1 mg | pink round tablet, 8 mm, scored to split in 2 | IG W 1 |
| 2 mg | purple round tablet, 8 mm, scored to split in 2 | IG W 2 |
| 2.5 mg | green round tablet, 8 mm, scored to split in 2 | IG W 2 1 2 |
| 3 mg | brown round tablet, 8 mm, scored to split in 2 | IG W 3 |
| 4 mg | blue round tablet, 8 mm, scored to split in 2 | IG W 4 |
| 5 mg | orange round tablet, 8 mm, scored to split in 2 | IG W 5 |
| 7.5 mg | yellow round tablet, 8 mm, scored to split in 2 | IG W 7 1 2 |
| 10 mg | white round tablet, 8 mm, scored to split in 2 | IG W 10 |
Pd-Rx Pharmaceuticals, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 5 mg | orange oval tablet, 11 mm, scored to split in 2 | TV 5 1721 |
Preferred Pharmaceuticals Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 2.5 mg | green oval tablet, 11 mm, scored to split in 2 | 763 2 1 2 AN |
Teva Pharmaceuticals USA, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 1 mg | pink oval tablet, 11 mm, scored to split in 2 | TV 1 1712 |
| 2 mg | purple oval tablet, 11 mm, scored to split in 2 | TV 2 1713 |
| 2.5 mg | green oval tablet, 11 mm, scored to split in 2 | TV 2 1 2 1714 |
| 3 mg | brown oval tablet, 11 mm, scored to split in 2 | TV 3 1715 |
| 4 mg | blue oval tablet, 11 mm, scored to split in 2 | TV 4 1716 |
| 5 mg | orange oval tablet, 11 mm, scored to split in 2 | TV 5 1721 |
| 6 mg | turquoise oval tablet, 11 mm, scored to split in 2 | TV 6 1718 |
| 7.5 mg | yellow oval tablet, 11 mm, scored to split in 2 | TV 7 1 2 1719 |
| 10 mg | white oval tablet, 11 mm, scored to split in 2 | TV 10 1720 |
Upsher-Smith Laboratories, LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 1 mg | pink round tablet, 9 mm, scored to split in 2 | WRF 1 832 |
| 2 mg | purple round tablet, 9 mm, scored to split in 2 | WRF 2 832 |
| 2.5 mg | green round tablet, 9 mm, scored to split in 2 | WRF 2 1 2 832 |
| 3 mg | brown round tablet, 9 mm, scored to split in 2 | WRF 3 832 |
| 4 mg | blue round tablet, 9 mm, scored to split in 2 | WRF 4 832 |
| 5 mg | orange round tablet, 9 mm, scored to split in 2 | WRF 5 832 |
| 6 mg | turquoise round tablet, 9 mm, scored to split in 2 | WRF 6 832 |
| 7.5 mg | yellow round tablet, 9 mm, scored to split in 2 | WRF 7 1 2 832 |
| 10 mg | white round tablet, 9 mm, scored to split in 2 | WRF 10 832 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
1 recall since 2020
- Jan 2022 · Cardinal Healthcare · Class II
CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.